Cargando…
Clinical and radiological features driving patient selection for antiangiogenic therapy in non-small cell lung cancer (NSCLC)
BACKGROUND: The use of antiangiogenic therapy in non-small cell lung cancer (NSCLC) requires thorough evaluation of patient characteristics in order to avoid potential safety issues, particularly pulmonary haemorrhage (PH). The aim of this consensus by a panel of experts was to identify important cr...
Autores principales: | Gridelli, Cesare, Camerini, Andrea, Pappagallo, Giovanni, Pennella, Angelo, Anzidei, Michele, Bellomi, Massimo, Buosi, Roberta, Grasso, Rosario Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5192596/ https://www.ncbi.nlm.nih.gov/pubmed/28031049 http://dx.doi.org/10.1186/s40644-016-0102-4 |
Ejemplares similares
-
The role of antiangiogenic monoclonal antibodies combined to EGFR-TKIs in the treatment of advanced non-small cell lung cancer with activating EGFR mutations: acquired resistance mechanisms and strategies to overcome them
por: Rocco, Danilo, et al.
Publicado: (2022) -
The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC
por: Zhou, Ling, et al.
Publicado: (2023) -
Antiangiogenic VEGF Isoform in Inflammatory Myopathies
por: Volpi, Nila, et al.
Publicado: (2013) -
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
por: Pang, Lan-Lan, et al.
Publicado: (2023) -
Outcome of Thromboembolic Events and Its Influence on Survival Time of Advanced NSCLC Patients Treated with Antiangiogenic Therapy
por: Ou, Wei-Fan, et al.
Publicado: (2023)